Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: NUTROPIN DEPOT

« Back to Dashboard
Nutropin Depot is a drug marketed by Genentech and is included in one NDA. There are two patents protecting this drug.

The generic ingredient in NUTROPIN DEPOT is somatropin recombinant. There are two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the somatropin recombinant profile page.

Summary for Tradename: NUTROPIN DEPOT


Clinical Trials for: NUTROPIN DEPOT

Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study
Status: Terminated Condition: Growth Hormone Deficiency (GHD)

Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects
Status: Completed Condition: Growth Hormone Deficiency

Genotropin Study Assessing Use of Injection Pen
Status: Completed Condition: Growth Hormone Deficiency; Idiopathic Short Stature

An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)
Status: Recruiting Condition: Adult Growth Hormone Deficiency

Growth Hormone Use in Albright Hereditary Osteodystrophy
Status: Recruiting Condition: Pseudohypoparathyroidism Type 1a; Albright Hereditary Osteodystrophy

Effects of Short-term Growth Hormone in HIV-infected Patients
Status: Completed Condition: HIV Lipodystrophy

Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device
Status: Completed Condition: Turner's Syndrome; Human Growth Hormone Deficiency

Clinical Trial of Growth Hormone in MPS I, II, and VI
Status: Terminated Condition: Mucopolysaccharidosis I; Mucopolysaccharidosis II; Mucopolysaccharidosis VI

Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)
Status: Completed Condition: Growth Hormone Deficiency

Drug Use Investigation of Somatropin for GHD-ADULTS.
Status: Completed Condition: Dwarfism, Growth Hormone Deficiency

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
somatropin recombinant
INJECTABLE;INJECTION021075Dec 22, 1999DISCNNo5,654,010<disabled><disabled>
somatropin recombinant
INJECTABLE;INJECTION021075Dec 22, 1999DISCNNo5,656,297<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: NUTROPIN DEPOT

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
August 05, 2009
August 12, 2009
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn